HEPARIN
Cancer of Liver
H. Lee Moffitt Cancer Center and Research InstitutemixtureN/AActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Cancer of Liver cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bxcl501 Uppsala University Hospital | Phase 4 | BBB |
Rapamycin University of Chicago | Phase 1 | CCC |
Bortezomib Leaf Vertical Inc. | Phase 1/2 | CCC |
Amsulostat University of Rochester | Phase 1/2 | CCC |
PREDNISONE TABLETS Leaf Vertical Inc. | Phase 1/2 | CCC |
Metformin University of Chicago | Phase 1 | CC |
Gm-Csf Lisa H. Butterfield, Ph.D. | Phase 1 | CC |
Catequentinib IRCCS Azienda Ospedaliero-Universitaria di Bologna | N/A | D |
Same molecule, other indications
HEPARIN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →